PRIME is a European consortium of research institutes, medical centres, companies, and societal stakeholders that is funded t ... hrough an EU Horizon 2020 grant. From 2020 – 2024, PRIME will aim to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders (i.e. Alzheimer’s disease, obsessive-compulsive disorder, autism spectrum disorders). Until now, very little attention has been paid to the role of insulin signaling in brain disorders, and the overlap (or ‘multimorbidity’) with somatic conditions. Therefore, through PRIME, we aim to develop tools for improved diagnosis, clinical care and prevention of insulin-related lifespan multimorbidity. read more